Skip to main content
. Author manuscript; available in PMC: 2020 Feb 28.
Published in final edited form as: Nature. 2019 Jul 10;571(7766):576–579. doi: 10.1038/s41586-019-1382-1

Fig. 4: Context-specific therapeutic sensitivity of BRCA1/2-mutant tumors.

Fig. 4:

a) Left, clinical benefit to PARP inhibitor therapy in patients with BRCA-associated cancer types with and without BRCA1/2 mutations (germline or somatic) (HR 0.58, 95% CI 0.46–0.73, log-rank p-value=3.7e-6). Right, patients with all other cancer types (HR 1.02, 95% CI 0.6–1.7, log-rank p-value=0.98). b) In BRCA-associated cancer types, clinical benefit to PARP inhibition in patients with somatic LoF versus germline pathogenic BRCA1/2 alterations. c) As in panel (b) but comparing clinical benefit in heterozygous versus biallelic BRCA1/2-mutant BRCA-associated cancers. d-e) Event-free survival from the start of the first line of immune checkpoint blockade therapy in patients pan-cancer with or without BRCA1/2 germline or somatic mutations (HR=0.99, p-value=0.9 for non-hypermutated tumors). Multivariable model includes tumor mutational burden (>75th percentile) and affected cancer type.